Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population

被引:1
|
作者
Hainfellner, Andreas [1 ,2 ]
Borkovec, Martin [1 ]
Seebrecht, Lukas [1 ]
Neuhauser, Magdalena [1 ]
Roetzer-Pejrimovsky, Thomas [1 ]
Greutter, Lisa [1 ,3 ]
Surboeck, Birgit [4 ]
Hager-Seifert, Andrea [5 ]
Gorka-vom Hof, Doris [6 ]
Urbanic-Purkart, Tadeja [6 ]
Stultschnig, Martin [7 ]
Cijan, Clemens [7 ]
Wuertz, Franz [8 ]
Calabek-Wohinz, Bernadette [9 ]
Pichler, Josef [10 ]
Hoellmueller, Isolde [10 ]
Leibetseder, Annette [11 ]
Weis, Serge [12 ,13 ]
Kleindienst, Waltraud [14 ]
Seiberl, Michael [14 ]
Bieler, Lara [14 ]
Hecker, Constantin [14 ,15 ]
Schwartz, Christoph [15 ]
Iglseder, Sarah [16 ]
Heugenhauser, Johanna [16 ]
Nowosielski, Martha [16 ]
Thome, Claudius [17 ]
Moser, Patrizia [18 ]
Hoffermann, Markus [19 ]
Loibnegger, Karin [20 ]
Dieckmann, Karin [21 ]
Tomschik, Matthias [22 ]
Widhalm, Georg [22 ]
Roessler, Karl [22 ]
Marosi, Christine [23 ,24 ]
Woehrer, Adelheid [1 ]
Hainfellner, Johannes A. [1 ]
Oberndorfer, Stefan [9 ,25 ]
机构
[1] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, Dept Neurol,Div Neuropathol & Neurochem, Med Univ Campus AKH 4J,Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ctr Anat & Cell Biol, Div Anat, Vienna, Austria
[3] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria
[4] Clin Favoriten, Dept Neurol, Vienna, Austria
[5] State Hosp Wr Neustadt, Dept Neurol, Wr Neustadt, Austria
[6] Med Univ Graz, Dept Neurol, Graz, Austria
[7] State Hosp Klagenfurt, Dept Pathol, Klagenfurt, Austria
[8] State Hosp Klagenfurt, Dept Pathol, Klagenfurt, Austria
[9] Univ Hosp St Polten, Dept Neurol, Dunant Pl 1, A-3100 St Polten, Austria
[10] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Internal Med & Neurooncol, Neuromed Campus, Linz, Austria
[11] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Neurol 1, Neuromed Campus, Linz, Austria
[12] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Pathol & Mol Pathol, Div Neuropathol, Neuromed Campus, Linz, Austria
[13] Johannes Kepler Univ Linz, Clin Res Inst Neurosci, Linz, Austria
[14] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurol, Salzburg, Austria
[15] Paracelsus Med Univ Salzburg, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria
[16] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[17] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria
[18] Tirol Kliniken GmbH, Lab Neuropathol, Innsbruck, Austria
[19] State Hosp Feldkirch, Dept Paediat, Feldkirch, Austria
[20] State Hosp Feldkirch, Dept Radiat Oncol, Feldkirch, Austria
[21] Med Univ Vienna, Comprehens Canc Ctr, Dept Radiat Oncol, Vienna, Austria
[22] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, Dept Neurosurg, Vienna, Austria
[23] Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Comprehens Canc Ctr, Vienna, Austria
[24] Med Univ Vienna, Dept Internal Med 1, Div Oncol, Vienna, Austria
[25] Univ Hosp St Polten, Karl Landsteiner Inst Clin Neurol & Neuropsychol, Dept Neurol, St Polten, Austria
关键词
Glioblastoma; Prognosis; Outcome; Registry; NEWLY-DIAGNOSED GLIOBLASTOMA; BRAIN-TUMOR REGISTRY; 5-AMINOLEVULINIC ACID; TEMOZOLOMIDE THERAPY; PROGNOSTIC-FACTORS; SURVIVAL; RADIOTHERAPY; RESECTION; ASSOCIATION; EXTENT;
D O I
10.1007/s11060-024-04808-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We present results of a retrospective population-based investigation of patterns of care and outcome of glioblastoma patients in Austria. Patients and methods In this nation-wide cooperative project, all Austrian glioblastoma patients newly diagnosed between 2014 and 2018 and registered in the ABTR-SANOnet database were included. Histological typing used criteria of the WHO classification of CNS tumors, 4th edition 2016. Patterns of care were assessed, and all patients were followed until the end of 2019. Results 1,420 adult glioblastoma cases were identified. 813 (57.3%) patients were male and 607 (42.7%) female. Median age at diagnosis was 64 years (range: 18-88). Median overall survival (OS) was 11.6 months in the total cohort and 10.9 months in patients with proven IDH-wildtype. Median OS in the patient group <= 65 years receiving postoperative standard of care therapy was 16.1 months. In the patient group > 65 years with postoperative therapy, median OS was 11.2 months. Follow-up >= 5 years identified 13/264 (4.9%) long-term survivors. Brain tumor surgery frequently was assisted by 5-aminolevulinic acid (5-ALA) fluorescence (up to 55%). Postoperative treatment was initiated around one month after surgery (median: 31 days) following standardized protocols in 1,041/1,420 (73.3%) cases. In 830 patients (58.5%), concomitant radiochemotherapy was started according to the established standard of care. Treatment in case of progressive disease was considerably variable. 170/1,420 patients (12.0%) underwent a second surgical procedure, 467 (33.0%) received systemic treatment after progression, and 173 (12.2%) were re-irradiated. Conclusion Our data illustrate and confirm nation-wide translation of effective standard of care to Austrian glioblastoma patients in the recent past. In the case of progressive disease, highly variable therapeutic approaches were used, most frequently accompanied by anti-angiogenic therapy. Long-term survival was observed in a minor proportion of mostly younger patients who typically had gross total tumor resection, a favorable postoperative ECOG score, and standard of care therapy.
引用
收藏
页码:407 / 418
页数:12
相关论文
共 50 条
  • [21] TREATMENT PATTERNS IN OVERACTIVE BLADDER: REAL-WORLD PATIENT POPULATION
    Ellsworth, P.
    Bavendam, T.
    Zou, K. H.
    Mastey, V
    Chen, C., I
    VALUE IN HEALTH, 2011, 14 (03) : A75 - A75
  • [22] TREATMENT PATTERNS IN MIGRAINE: A REAL-WORLD ANALYSIS IN A US POPULATION
    Lombard, L.
    Ford, J.
    Jackson, J.
    Milligan, G.
    Cotton, S.
    Ahl, J.
    CEPHALALGIA, 2016, 36 : 29 - 30
  • [23] Delirium care: Real-world solutions to real-world problems
    Eeles, Eamonn
    McCrow, Judy
    Teodorczuk, Andrew
    Caplan, Gideon A.
    AUSTRALASIAN JOURNAL ON AGEING, 2017, 36 (04) : E64 - E69
  • [24] Real-World Data on Canagliflozin in Managed Care Setting Presented at ADA
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 : 7 - +
  • [25] Does Pay for Performance Improve Cardiovascular Care in a "Real-World" Setting?
    Chen, Judy Ying
    Tian, Haijun
    Juarez, Deborah Taira
    Yermilov, Irina
    Braithwaite, Ronald S.
    Hodges, Krista A.
    Legorreta, Antonio
    Chung, Richard S.
    AMERICAN JOURNAL OF MEDICAL QUALITY, 2011, 26 (05) : 340 - 348
  • [26] Efficacy of Omalizumab in a real-world setting
    Sussman, Robert
    CHEST, 2007, 132 (04) : 512S - 512S
  • [27] Experience with dulaglutide in a real-world setting
    Zouras, S.
    Stephens, J. W.
    Price, D. E.
    Syed, W.
    DIABETIC MEDICINE, 2018, 35 : 186 - 186
  • [28] Hidden altruism in a real-world setting
    Raihani, N. J.
    BIOLOGY LETTERS, 2014, 10 (01)
  • [29] Insulin thermostability in a real-world setting
    Pendsey, Sanket
    James, Steven
    Garrett, Timothy J.
    Nord, Anders Bay
    Pendsey, Sharad
    Malmodin, Daniel
    Karlsson, Goran
    Maniam, Jayanthi
    Atkinson, Mark A.
    Forsander, Gun
    Ogle, Graham D.
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (05): : 310 - 312
  • [30] Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis
    Tkacz, Joseph
    Lewing, Benjamin
    Feliciano, Joseph
    Mohanty, Maitreyee
    Lauterio, Melanie
    Fucile, Sebastian
    Barker, Alan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (09): : 967 - 977